194 related articles for article (PubMed ID: 38262637)
1. Experiences and perspectives on chimeric antigen receptor (CAR) T-cell therapy among recipients, carers and referrers (RE-TELL): a qualitative study to inform CAR T-cell service design.
Fyfe R; Anstis O; Kapadia K; Jordan M; Sword DO; Weinkove R
BMJ Open; 2024 Jan; 14(1):e071112. PubMed ID: 38262637
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor T-cells in New Zealand: challenges and opportunities.
Weinkove R; George P; Ruka M; Haira TH; Giunti G
N Z Med J; 2021 Sep; 134(1542):96-108. PubMed ID: 34531588
[TBL] [Abstract][Full Text] [Related]
3. A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: Recommendations for service development and implications for palliative care teams.
Stenson CL; Vidrine J; Dewhurst F; Osborne W; Menne T; Stocker R
Palliat Med; 2023 Feb; 37(2):215-220. PubMed ID: 36428287
[TBL] [Abstract][Full Text] [Related]
4. Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial.
Castillo G; Lalu MM; Asad S; Foster M; Kekre N; Fergusson DA; Hawrysh T; Atkins H; Thavorn K; Montroy J; Schwartz S; Holt RA; Broady R; Presseau J
BMJ Open; 2021 Mar; 11(3):e043929. PubMed ID: 33741670
[TBL] [Abstract][Full Text] [Related]
5. Experiences and perspectives of individuals accessing CAR-T cell therapy: A qualitative analysis of online Reddit discussions.
Jenei K; Burgess M; Peacock S; Raymakers AJN
J Cancer Policy; 2021 Dec; 30():100303. PubMed ID: 35559799
[TBL] [Abstract][Full Text] [Related]
6. Patients' experience with chimeric antigen receptor T-cell therapy for DLBCL in China: a qualitative study.
Mao Y; Huang L; Ruan H; Guo Y; Ni S; Ling Y
Support Care Cancer; 2023 Apr; 31(5):303. PubMed ID: 37099077
[TBL] [Abstract][Full Text] [Related]
7. Protocol for a mixed-methods study to develop and feasibility test a digital system for the capture of patient-reported outcomes (PROs) in patients receiving chimeric antigen receptor T-cell (CAR-T) therapies (the PRO-CAR-T study).
Hughes SE; McMullan C; Aiyegbusi OL; Shaw K; Kinsella F; Ferguson P; Khatsuria F; Burns D; Pyatt L; Ansell J; Chakera E; Richardson-Abraham J; Denniston AK; Davies EH; Craddock C; Calvert M
BMJ Open; 2024 Mar; 14(3):e085392. PubMed ID: 38553074
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
9. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
[TBL] [Abstract][Full Text] [Related]
10. Oncology nurse competency in chimeric antigen receptor T-cell therapy: A qualitative study.
He J; Li J; Feng LN; Feng LX; Qiang W; Wang W; Dong L
Nurse Educ Today; 2024 Jan; 132():106040. PubMed ID: 37956569
[TBL] [Abstract][Full Text] [Related]
11. Patient experiences and perspectives of health service access for carpal tunnel syndrome in Aotearoa New Zealand: a normalisation process theory-informed qualitative study.
Bűhler M; Atmore C; Perry M; Crengle S; Norris P; Baxter GD
BMC Health Serv Res; 2024 Apr; 24(1):465. PubMed ID: 38614968
[TBL] [Abstract][Full Text] [Related]
12. Reimagining eating disorder spaces: a qualitative study exploring Māori experiences of accessing treatment for eating disorders in Aotearoa New Zealand.
Clark MTR; Manuel J; Lacey C; Pitama S; Cunningham R; Jordan J
J Eat Disord; 2023 Feb; 11(1):22. PubMed ID: 36793068
[TBL] [Abstract][Full Text] [Related]
13. Multi-Stakeholder Qualitative Interviews to Inform Measurement of Patient Reported Outcomes After CAR-T.
Akinola IM; Cusatis R; Pasquini MC; Shaw BE; Bollu V; Dalal A; Tesfaye M; Flynn KE
Transplant Cell Ther; 2023 Apr; 29(4):254.e1-254.e9. PubMed ID: 36634738
[TBL] [Abstract][Full Text] [Related]
14. The Patient Symptom Experience After Tisagenlecleucel and Lisocabtagene Maraleucel CAR T-Cell Therapy for Lymphoma.
Andersen L; Baker KM; Difilippo H; Meghani SH; Porter D; Deng J
Semin Oncol Nurs; 2024 Apr; 40(2):151614. PubMed ID: 38443220
[TBL] [Abstract][Full Text] [Related]
15. Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy.
Barata A; Hoogland AI; Hyland KA; Otto AK; Kommalapati A; Jayani RV; Irizarry-Arroyo N; Collier A; Rodriguez Y; Welniak TL; Booth-Jones M; Logue J; Small BJ; Jain MD; Reblin M; Locke FL; Jim HSL
Psychooncology; 2021 Aug; 30(8):1294-1301. PubMed ID: 33739548
[TBL] [Abstract][Full Text] [Related]
16. A Primer on Chimeric Antigen Receptor T-cell Therapy: What Does It Mean for Pathologists?
Cushman-Vokoun AM; Voelkerding KV; Fung MK; Nowak JA; Thorson JA; Duncan HL; Kalicanin T; Anderson MW; Yohe S
Arch Pathol Lab Med; 2021 Jun; 145(6):704-716. PubMed ID: 33237994
[TBL] [Abstract][Full Text] [Related]
17. Communication About Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.
Dhawale T; Johnson PC; Boateng K; Barata A; Traeger L; Nelson AM; Lavoie MW; Holmbeck K; Choe J; Nabily A; Tripathi A; Amonoo HL; Frigault M; El-Jawahri A
Transplant Cell Ther; 2024 Apr; 30(4):402.e1-402.e12. PubMed ID: 38262530
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma.
Seyedin R; Snider JT; Rajagopalan K; Wade SW; Gergis U
Future Oncol; 2023 Jul; 19(22):1535-1547. PubMed ID: 37578377
[TBL] [Abstract][Full Text] [Related]
19. Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma.
Hoda D; Richards R; Faber EA; Deol A; Hunter BD; Weber E; DiFilippo H; Henderson-Clark T; Meaux L; Crivera C; Riccobono C; Garrett A; Jackson CC; Fowler J; Theocharous P; Stewart R; Lorden AL; Porter DL; Berger A
Future Oncol; 2022 Jun; 18(19):2415-2431. PubMed ID: 35583358
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T
Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
